Status:
TERMINATED
A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Chronic Kidney Disease
Hyperphosphatemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Approximately 207 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 50 sites within approximately 9 European countries. The purpose of this study is to de...
Eligibility Criteria
Inclusion
- Serum phosphorus measurement ≥4.6 mg/dL (≥1.49 mmol/L) and ≤5.5 mg/dL (≤1.76 mmol/L after discontinuation of current phosphate binder therapy if applicable.
Exclusion
- Active dysphagia or swallowing disorder or a predisposition to or current bowel obstruction, ileus, or severe gastrointestinal motility disorders including severe constipation.
Key Trial Info
Start Date :
January 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00833768
Start Date
January 1 2009
End Date
September 1 2009
Last Update
March 24 2015
Active Locations (36)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitätsklinik für Innere Medizin, Klinische Abteilung für Nephrologie und Hämodialyse
Graz, Austria
2
Uniklinik für Innere Medizin IV, Nephrologie und Hypertensiologie, Zentrum für Innere Medizin, Medizinische Universität Innsbruck
Innsbruck, Austria
3
Krankenhaus der Elisabethinen Linz, 3. Abteilung Schwerpunkt Nephrologie
Linz, Austria
4
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie und Dialyse
Vienna, Austria